Frontpage Hero

Because we care, we need to act

Statement from the CEO

Building for balance and growth

"Sobi is delivering on a solid strategy for growth. Building on our strength in Haemophilia, we aim to grow the business with a broader Specialty Care portfolio to ensure long-term sustainability and strength and make a real difference for people with rare diseases."

Press releases

Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the company has gained reimbursement for Ravicti®, a new therapy option for the treatment of patients with Urea Cycle Disorders (UCDs) in several EU member states and EEA-countries. Sweden, Denmark, Austria and Germany are the first countries...

03/21/2018 - 08:00

Swedish Orphan Biovitrum AB (publ) (Sobi™) announces today, on Rare Disease Day, the launch of an enhanced corporate sustainability programme with a strong connection to the company’s strategy of providing sustainable access to treatments for rare diseases.

As part of the new sustainability strategy...

02/28/2018 - 14:00

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Henrik Stenqvist will be appointed Chief Financial Officer (CFO) and will join Sobi in late spring. Henrik will be a member of Sobi’s Executive Committee.

Henrik Stenqvist has comprehensive experience from the pharmaceutical industry...

02/26/2018 - 08:05

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for anakinra for the treatment of Still’s disease. The opinion is now referred to the European Commission...

02/23/2018 - 15:55
Contact us

Sobi Head Office
+46 8 697 20 00
Tomtebodavägen 23A
SE-112 76 Stockholm, Sweden